[Media coverage] Thymus-focused T-cell therapy platform draws EU funding to startup Smart Immune

Smart Immune having been recently selected by the European Innovation Council for a funding of €17.5, our CEO Karine Rossignol was featured in Bioworld published by Clarivate. Among other things, the ProTcell platform's ability to rebuild a patient's T-cell compartment in three months, compared to one to two years for a conventional bone marrow transplant, was addressed.

Thanks to this technology, it is hoped that reducing the duration of immunosuppression will reduce the risk of infection and relapse for patients.

See article: Thymus-focused T-cell therapy platform draws EU funding to startup Smart Immune

‍

Karine Rossignol said: The backing of the European Innovation Council is a recognition that the ProTcell platform “is a potential game-changer”.

‍